Get Started

CYDY

OQB CytoDyn Inc.
Nov 4, 2026 · 8:37 AM ET EOD Market Closed

$0.2263 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2263, $0.0177 below the day’s high of $0.2440

YTD change
-19.18%
vs 20-day SMA
+2.56%
vs 200-day SMA
-10.04%

Price ranges

Previous day
$0.2200 $0.2440
open $0.2250 close $0.2263
+$0.0013 (+0.58%)
Today
$0.2200 $0.2440
$0.2263
Past week
$0.2120 $0.2429
from $0.2392 now $0.2263
-$0.0129 (-5.41%)
Past month
$0.1970 $0.2900
from $0.2000 now $0.2263
+$0.0263 (+13.15%)
This year
$0.1829 $0.3970
from $0.2800 now $0.2263
-$0.0537 (-19.18%)

Price & Performance

-0.08 (-25.78%) / 6M

$0.1729$0.2385$0.3040$0.3696May 4Aug 4Nov 3

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 97.7% away from all-time highs of $10.0100
  • CYDY is down 19% since the beginning of the year
  • CYDY is down 14% over the past 12 months
  • CYDY is up 13% over the past 1 month
  • 2% of all CYDY investors are betting against CYDY

CYDY reads not so good: price sits above one of the two key moving averages, the 12-month move is -8.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.0147
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $315.1M
Beta 1.45

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$16.4M
Debt$27.3K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeOQB
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $332.6M

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development and potential commercialization of its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its current clinical development activities focus on solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer, and the development of a long-acting version of leronlimab. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $973.36 +1.26%
IQV IQVIA Holdings Inc $262.59 +1.61%
CRL Charles River Laboratories International, Inc. $351.87 +3.94%
ICLR ICON Plc $203.77 -0.67%
IT Gartner, Inc. $204.22 -13.19%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.